BeiGene completes redomestication to Switzerland, renamed BeOne Medicines Ltd.

BeOne Medicines Ltd.

Effective May 27, 2025, BeiGene continued from Cayman Islands to Switzerland, becoming BeOne Medicines Ltd.
New Swiss Articles and Organizational Regulations govern shareholder rights; ADSs continue on Nasdaq under ONC.
Executive employment agreements executed with CEO Oyler ($1.133M base), President Wu (RMB 6.0M), CFO Rosenberg ($660K), R&D head Wang (RMB 4.59M), and GC Lee ($654K).
Amended deposit agreement with Citibank and new indemnification agreements for directors and officers adopted.
Ordinary shares listed on HKEX (06160) and Shanghai STAR Market (688235) remain unchanged.

item 1.01item 3.03item 8.01item 5.02item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.